Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171522

Enrollment

Registered

2005-09-15

Start date

2005-05-31

Completion date

2005-09-30

Last updated

2016-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation

Keywords

Constipation, Tegaserod, Polyethylene Glycol 3350, PEG

Brief summary

To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste

Interventions

DRUGTegaserod and Polyethylene Glycol 3350

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 64 Years

Inclusion criteria

* Females aged 18 to 64 years of age * Patients with constipation as defined by the Rome II criteria

Exclusion criteria

* Patients who have been previously been treated with tegaserod and/or PEG 3350 * Evidence of cathartic colon or a history of laxative abuse or laxative dependence * History of fecal impaction which necessitated surgical intervention * Patients with clinically significant abnormal TSH levels at screening * Women who are pregnant or breast feeding Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
To determine after 14 / 35 days of treatment if women with constipation have a preference for tegaserod compared to PEG 3350, based on the assessment of the Constipation Treatment questionnaire (satisfaction with treatment, willingness to re-use)	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026